We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gut Microbes Differ Between Two Common Conditions

By LabMedica International staff writers
Posted on 01 Jan 2019
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two of the most common diseases of the gastrointestinal tract. More...
Unlike IBD, IBS does not cause inflammation, ulcers or other damage to the bowel.

Instead, IBS is a much less serious problem called a functional disorder. This means that the digestive system looks normal but does not work as it should. Symptoms of IBS may include cramps, bloating, gas, diarrhea, constipation and mucus in the stool. IBS has also been called spastic colon or spastic bowel.

An international team of scientists led by the University of Groningen (Groningen, Netherlands) performed metagenomic sequencing on stool samples from 355 individuals with IBD (Crohn's disease or ulcerative colitis), 412 individuals with IBS, and 1,025 unaffected, healthy controls, searching for microbial species and strains associated with one or both inflammatory gut conditions.

The team performed shotgun metagenomic sequencing used Illumina instruments on microbial DNA in home-collected stool samples from 1,792 well-phenotyped cases and controls from three cohorts from the Netherlands. The team's sequence data led to 219 Crohn's disease-related taxa, 102 taxa associated with ulcerative colitis, and 66 taxa with apparent ties to IBS. There was some overlap between conditions: Within IBD, for example, at least 87 of the microbes implicated in ulcerative colitis also turned up in individuals with Crohn's disease.

The scientist noted that the diversity of strains within beneficial bacterial species, such as Faecalibacterium prausnitzii, tended to wane in the guts of individuals with IBD or IBS relative to the unaffected controls. They also saw shifts in strain diversity for 21 bacterial species in individuals with Crohn's disease, compared to strain diversity changes in 15 species in those with ulcerative colitis and one species in the IBS group. The team also estimated growth rates for a subset of the gut microbial species, identifying small sets of species that seemed to have altered abundance in each of the conditions. In addition, they investigated the differences in bacterial composition, gene content, and gene functions in the IBD and IBS cases.

The authors concluded that despite substantial overlap between the gut microbiome of patients with IBD and IBS compared with control individuals, they were able to use gut microbiota composition differences to distinguish patients with IBD from those with IBS. By combining species-level profiles and strain-level profiles with bacterial growth rates, metabolic functions, antibiotic resistance, and virulence factor analyses, they identified key bacterial species that may be involved in two common gastrointestinal diseases. The study was published on December 19, 2018, in the journal Science Translational Medicine.

Related Links:
University of Groningen


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.